Emmaus Life Sciences, Inc. (OTCQX: EMMA), a California-based company involved in sickle cell disease (SCD) treatment, announced on Friday that it has received marketing authorisation from the Puerto Rico Department of Health for Endari (L-glutamine oral powder).
The company says that the approval represents a significant milestone in the company's mission to improve the lives of people with SCD around the world and provides access to this therapy for the patients living with SCD in Puerto Rico. The product is also approved in the United States, Israel, United Arab Emirates, Kuwait, Qatar, Bahrain, and Oman.
Endari is the first FDA-approved oral glutamine therapy for the reduction of acute complications of SCD in adult and paediatric patients five years and older. Clinical studies have indicated that the product can significantly reduce the frequency of pain crises, hospitalisations and other acute complications of SCD.
Akura Medical's application for trial of Katana Thrombectomy System receives US FDA approval
FDA accepts Ionis Pharmaceuticals' donidalorsen New Drug Application
Kazia Therapeutics secures FDA meeting to explore paxalisib pathways for glioblastoma
Boston Scientific to acquire Cortex Inc in strategic expansion of electrophysiology portfolio
Formosa Pharmaceuticals signs licensing agreement with DÁVI Farmaceutica
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation
Eisai completes rolling BLA submission for lecanemab-irmb to FDA
Satsuma Pharmaceuticals and Shin Nippon Biomedical resubmit STS101 NDA to FDA
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
Sobi to present emapalumab data for treating macrophage activation syndrome at ACR Conference
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI